AstraZeneca

Hello World

AZ’s Bydureon disappoints in diabetes outcomes trial

May 23, 2017

Results give advantage to Boehringer/Lilly’s Jardiance.

AZ’s Bydureon disappoints in diabetes outcomes trial

https://pharmaphorum.com/news/azs-bydureon-disappoints-diabetes-outcomes-trial/

European regulators back Chiesi COPD triple therapy

May 22, 2017

Chiesi takes on Seretide and other lung drugs with Trimbow.

European regulators back Chiesi COPD triple therapy

https://pharmaphorum.com/news/european-chiesi-copd-therapy/

AZ sells beta-blocker rights to Recordati for $300m

May 22, 2017

Italian pharma gets EU rights to Seloken.

AZ sells beta-blocker rights to Recordati for $300m

https://pharmaphorum.com/news/az-sells-rights-recordati/

The week that turned the cancer immunotherapy market on its head

May 12, 2017

Contrasting fortunes for Roche and AZ in a week of drama.

The week that turned the cancer immunotherapy market on its head

https://pharmaphorum.com/news/cancer-immunotherapy/

Drama as Roche’s Tecentriq fails in key bladder cancer trial

May 11, 2017

Roche has been shocked by the late-stage trial failure of its immunotherapy Tecentriq in bladder cancer, a setback which could

Drama as Roche’s Tecentriq fails in key bladder cancer trial

https://pharmaphorum.com/news/drama-roche-tecentriq-fails-key-bladder-cancer-trial/

AZ failure cast further doubts over IL-13 drug asthma class

May 10, 2017

AZ waits for second set of results due later this year.

AZ failure cast further doubts over IL-13 drug asthma class

https://pharmaphorum.com/news/az-asthma-drug-failure-cast-doubts-il-13-drug-class/

AZ hopes to boost respiratory pipeline with Pieris deal

May 4, 2017

AstraZeneca is hoping to boost its respiratory pipeline in a deal potentially worth more than $2 billion with US biotech

AZ hopes to boost respiratory pipeline with Pieris deal

https://pharmaphorum.com/news/az-hopes-boost-respiratory-pipeline-pieris-deal/

AZ’s Imfinzi joins the immunotherapy contest

May 2, 2017

AZ hopes for blockbuster sales from Imfinzi.

AZ’s Imfinzi joins the immunotherapy contest

https://pharmaphorum.com/news/fda-approves-azs-durvalumab-immunotherapy-bladder-cancer/

AstraZeneca’s Cambridge R&D site build running years late

April 26, 2017

Building not operational until 2019, says CEO

AstraZeneca’s Cambridge R&D site build running years late

https://pharmaphorum.com/news/astrazeneca-new-cambridge-rd-site-build-running-years-late/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

AstraZeneca

Hello World

AZ’s Bydureon disappoints in diabetes outcomes trial

European regulators back Chiesi COPD triple therapy

AZ sells beta-blocker rights to Recordati for $300m

The week that turned the cancer immunotherapy market on its head

Drama as Roche’s Tecentriq fails in key bladder cancer trial

AZ failure cast further doubts over IL-13 drug asthma class

AZ hopes to boost respiratory pipeline with Pieris deal

AZ’s Imfinzi joins the immunotherapy contest

AstraZeneca’s Cambridge R&D site build running years late

FT Digital Health Summit Europe - London, 27 June 2017

4th Life Science Knowledge Management Summit

4th Clinical Regulatory Medical Writing Forum

GW close to filing cannabis-based epilepsy drug

AI-discovered candidates show promise in ALS

FDA advisers back Puma breast cancer drug despite safety worries

Keytruda wins another first with approval based on biomarkers

Orbita, ERT seek to improve voice-first data capture

Just how much does the NHS spend on medicines?

Patient-led trials: a formula for success

Health literacy: help pharma communicate with patients

Dynamic consent models can benefit clinical trials

Digital health round-up: the week of the WannaCry

Search

Advanced Search

Trending

AstraZeneca

Hello World